PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
15341931-0	2004	Novel pyrazinone inhibitors of mast cell tryptase: synthesis and SAR evaluation.	2-Hydroxypyrazine	6-16	tryptase delta 1	Homo sapiens	31-49
23085160-0	2012	Exploring the structure determinants of pyrazinone derivatives as PDE5 3HC8 inhibitors: an in silico analysis.	2-Hydroxypyrazine	40-50	phosphodiesterase 5A	Homo sapiens	66-70
23085160-8	2012	(5) Hydrophobic forces and pi-pi stacking interaction with Phe786 and Phe820 are crucial in determining the binding of pyrazinone derivatives to PDE5.	2-Hydroxypyrazine	119-129	phosphodiesterase 5A	Homo sapiens	145-149
19833844-0	2010	Comparative biotransformation of pyrazinone-containing corticotropin-releasing factor receptor-1 antagonists: minimizing the reactive metabolite formation.	2-Hydroxypyrazine	33-43	corticotropin releasing hormone receptor 1	Rattus norvegicus	55-96
19833844-10	2010	To reduce potential liability due to metabolic activation of BMS-665053, a number of pyrazinone analogs with different substituents were synthesized and investigated for reactive metabolite formation, leading to the discovery of a CRF-R1 antagonist with diminished in vitro metabolic activation.	2-Hydroxypyrazine	85-95	corticotropin releasing hormone receptor 1	Rattus norvegicus	231-237
19817410-4	2009	In addition, a pyrazinone-type Maillard product, 2-(5-(furan-2-yl)-6-methyl-2-oxopyrazin-1(2H)-yl) acetic acid (IIa), was identified as an intermediate for reaction product adduct II, whereas 3-deoxy-2-hexosulose was identified as an intermediate of adduct I.	2-Hydroxypyrazine	15-25	ATPase, class II, type 9A	Mus musculus	112-115
18821254-2	2008	Recent efforts in the development and biological evaluation of small molecule inhibitors of Akt have led to the identification of novel Akt kinase inhibitors, based on a quinoxaline or pyrazinone scaffold.	2-Hydroxypyrazine	185-195	AKT serine/threonine kinase 1	Homo sapiens	92-95
18821254-2	2008	Recent efforts in the development and biological evaluation of small molecule inhibitors of Akt have led to the identification of novel Akt kinase inhibitors, based on a quinoxaline or pyrazinone scaffold.	2-Hydroxypyrazine	185-195	AKT serine/threonine kinase 1	Homo sapiens	136-139
18606544-0	2008	Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP).	2-Hydroxypyrazine	26-36	prolyl endopeptidase	Homo sapiens	71-92
18606544-0	2008	Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP).	2-Hydroxypyrazine	26-36	prolyl endopeptidase	Homo sapiens	94-97
16137886-1	2005	Thrombin-inhibitor X-ray crystal structures, in combination with the installation of binding elements optimized within the pyrazinone series of thrombin inhibitors, were utilized to transform a weak triazolopyrimidine lead into a series of potent oxazolopyridines.	2-Hydroxypyrazine	123-133	coagulation factor II, thrombin	Homo sapiens	0-8
16137886-1	2005	Thrombin-inhibitor X-ray crystal structures, in combination with the installation of binding elements optimized within the pyrazinone series of thrombin inhibitors, were utilized to transform a weak triazolopyrimidine lead into a series of potent oxazolopyridines.	2-Hydroxypyrazine	123-133	coagulation factor II, thrombin	Homo sapiens	144-152
15890436-1	2005	The design, synthesis and biological activity of new thrombin inhibitors with a pyridinone or pyrazinone core and different heterobicyclic P(1) arginine side-chain mimetics are described.	2-Hydroxypyrazine	94-104	coagulation factor II, thrombin	Homo sapiens	53-61
15341931-1	2004	In this manuscript, the synthesis and SAR evaluation of a novel pyrazinone class of tryptase inhibitors is described.	2-Hydroxypyrazine	64-74	tryptase delta 1	Homo sapiens	84-92
12873514-1	2003	A series of potent and selective proline- and pyrazinone-based macrocyclic thrombin inhibitors is described.	2-Hydroxypyrazine	46-56	coagulation factor II, thrombin	Homo sapiens	75-83
14604352-2	2003	A six-step preparation of thrombin inhibitor drug candidate 1 from pyrazinone 7 in 47% overall yield is described.	2-Hydroxypyrazine	67-77	coagulation factor II, thrombin	Homo sapiens	26-34
12729670-1	2003	Part 6: design and synthesis of alphavbeta3 antagonists containing a pyridone or pyrazinone central scaffold.	2-Hydroxypyrazine	81-91	tankyrase 2	Homo sapiens	0-6
27020524-1	2016	A series of pyrazinone-based compounds incorporating either carbamate or aryl ether groups was synthesized and evaluated as corticotropin-releasing factor-1 (CRF1) receptor antagonists.	2-Hydroxypyrazine	12-22	corticotropin releasing hormone receptor 1	Homo sapiens	158-162
12588191-0	2003	Metabolic activation of a pyrazinone-containing thrombin inhibitor.	2-Hydroxypyrazine	26-36	coagulation factor II	Rattus norvegicus	48-56
32717614-2	2020	Evaluating the structure-activity relationship of an aminoalkyl substituent at the 3 position of the 2(1H)-pyrazinone core, p38alpha potency was increased 20000-fold.	2-Hydroxypyrazine	101-117	mitogen-activated protein kinase 14	Homo sapiens	124-132
29477077-0	2018	Pan-NS3 protease inhibitors of hepatitis C virus based on an R3-elongated pyrazinone scaffold.	2-Hydroxypyrazine	74-84	KRAS proto-oncogene, GTPase	Homo sapiens	4-7
29477077-1	2018	Herein, we present the design and synthesis of 2(1H)-pyrazinone based HCV NS3 protease inhibitors and show that elongated R3 urea substituents were associated with increased inhibitory potencies over several NS3 protein variants.	2-Hydroxypyrazine	47-63	KRAS proto-oncogene, GTPase	Homo sapiens	74-77
29477077-1	2018	Herein, we present the design and synthesis of 2(1H)-pyrazinone based HCV NS3 protease inhibitors and show that elongated R3 urea substituents were associated with increased inhibitory potencies over several NS3 protein variants.	2-Hydroxypyrazine	47-63	KRAS proto-oncogene, GTPase	Homo sapiens	208-211
27160057-0	2016	Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease.	2-Hydroxypyrazine	13-23	KRAS proto-oncogene, GTPase	Homo sapiens	127-130
27160057-1	2016	Herein, we present the design and synthesis of 2(1H)-pyrazinone based HCV NS3 protease inhibitors with variations in the C-terminus.	2-Hydroxypyrazine	47-63	KRAS proto-oncogene, GTPase	Homo sapiens	74-77
23517538-0	2014	Achiral pyrazinone-based inhibitors of the hepatitis C virus NS3 protease and drug-resistant variants with elongated substituents directed toward the S2 pocket.	2-Hydroxypyrazine	8-18	KRAS proto-oncogene, GTPase	Homo sapiens	61-64